Note: Most Internet Explorer 8 users encounter issues playing the presentation videos. Please update your browser or use a different one if available.

Whole-Exome and CNV Data for ASD Sex Bias

Saturday, 4 May 2013: 11:00
Chamber Hall (Kursaal Centre)
S. J. Sanders and M. W. State, Genetics, Yale University School of Medicine, New Haven, CT
Background: The predominance of male cases is amongst the most striking, consistent and unexplained observations in ASD. Recent papers have repeatedly highlighted the importance of de novo variants in ASD causation and these variants have been used to identify specific risk loci (e.g. 16p11.2, SCN2A). In this presentation we will consider what de novo and rare variation can contribute to understanding of the genomic architecture and mechanisms of ASD sex bias.

Objectives: To characterize how the distribution of de novo and rare variants in ASD probands differs between the sexes and to assess whether this data supports specific models of ASD sex bias.

Methods: Samples from the Simons Simplex Collection were analyzed by genotyping array (N=2,326 families; 309 female probands, 2,017 male probands) and whole-exome sequencing (N=964 families; 147 female probands; 761 male probands) to identify de novo and rare variants predicted to alter protein composition.

Results: Female probands consistently show a higher proportion of de novo variants than their male counterparts for both CNVs and loss of function (LoF, i.e. nonsense, canonical splice site and frameshift variants) variants. For de novo CNVs that include exons the difference is modest (9.1% of females vs. 5.4% of males, OR 1.76 (95% CI: 1.11-2.78), p=0.01), however considering only de novo CNVs implicated in clinical syndromes, such as 16p11.2, leads to a difference of a similar order to the sex bias observed in ASD (4.9% of females vs. 1.4% of males, OR 3.26 (95% CI: 1.82-7.14), p<0.001). From whole-exome sequencing a similar pattern emerges with a higher rate of de novo LoF in females (22.4% of females vs. 10.6% of males; OR 2.4 (95% CI 1.5-3.9), p<0.001); a similar non-significant trend is observed when the analysis is restricted to genes with ≥2 de novo LoF (a threshold at which they are considered ASD-associated) though only 21 individuals have such variants (4.1% of females vs. 2.0% of males; OR 2.12 (95% CI: 0.72-5.94), p=0.13). Finally while de novo CNV and LoF variants are observed on chrX, they are not seen at a greater rate than on other chromosomes.

Conclusions: In individuals diagnosed with ASD, risk-associated de novo variants occur more often in females than in males. Such an observation is consistent with a model of relative protection to ASD liability in females, but with the caveat that de novo events contribute sufficient risk that the protective mechanism is overwhelmed. In such a model the increase in de novo events is the consequence of a smaller proportion of females in whom ASD is caused by low risk inherited variation to which the females have protection. This model would explain the comparative similarity in recurrence rate of siblings to male and female probands (the ‘Carter Effect’). In summary the observation of increased de novo events in females with ASD supports a model of protection to inherited genetic risk in females.

See more of: Genetics
See more of: Genetic Factors in ASD
See more of: Biological Mechanisms
| More